30results about How to "Effective treatment" patented technology

The invention relates to a traditional Chinese medicine composition with functions of tonifying qi and nourishing blood for livestock. The traditional Chinese medicine composition comprises the following components in parts by weight: 10-30 parts of astragalus membranaceus, 10-40 parts of spina gleditsiae, 10-20 parts of angelica sinensis, 10-20 parts of codonopsis pilosula, 10-30 parts of uniflower swisscentaury root, 10-30 parts of ligusticum wallichii, 10-20 parts of cowherb seed, 10-20 parts of fruit of liquidambar formosana hance and 1-10 parts of iron sucrose. The traditional Chinese medicine composition is scientific and reasonable in component, free of toxic and side effects and medicine residue, convenient to take and low in cost, has the functions of tonifying qi and nourishing blood, stimulating the menstrual flow and prompting lactation, and is capable of effectively treating diseases of postpartum hypogalactia, breast milk stoppage and the like which are normal in livestock.

The present invention relates to novel multispecific binding proteins for cancer therapy, i.e. B7H6 / CD3 binding proteins. The invention further relates to nucleic acids encoding said proteins; methods for the production of said proteins; host cells expressing or capable of expressing said proteins; compositions comprising said proteins; and uses of said proteins or said compositions, in particular in the field of cancer diseases for therapeutic purposes.

This invention discloses a near-infrared light-exciteable composite nanosheet, its preparation method, and its applications, belonging to the field of biomedical technology. The method includes the following steps: mixing epigallocatechin gallate with a Ti3C2 nanosheet dispersion, ultrasonically reacting, adding silver salt, and continuing stirring in the dark; after the reaction is complete, washing and separating to obtain MXene-EGCG@Ag composite nanosheets. The composite nanosheets provided by this invention possess near-infrared light-exciteable properties and can be used to prepare medically acceptable dosage forms such as hydrogels for the treatment of periodontitis. The preparation method provided by this invention is simple, the raw materials are readily available, and it exhibits significant antibacterial and anti-inflammatory effects, enabling further widespread application.

An integrated eustachian tube sustained-release drainage device is provided with a drug-carryable, degradable and compressible elastic support, a drainage mechanism for draining liquid in the eustachian tube and a degradable connecting line, the drainage mechanism being fixed to the front end of the elastic support through the connecting line. The integrated eustachian tube drainage device can effectively drain the effusion and secretion in the eustachian tube, improve the ventilation and drainage conditions of the middle ear. The elastic support is composed of a degradable material and can carry drugs to continuously release the drugs, effectively treating diseases such as eustachian tube inflammation and reducing inflammatory reactions and promoting mucosal repair. Moreover, the degradable material of the elastic support reduces the long-term impact on the patient and reduces the risk of infection. The integrated eustachian tube drainage device can also be stably fixed in the eustachian tube, thereby improving the reliability of treatment.

An electro-acupuncture stimulation system comprises a first stimulation unit, a second stimulation unit and a control unit, the first stimulation unit is used for collecting a sensing signal of a first stimulation area and performing electro-acupuncture stimulation on the first stimulation area, the second stimulation unit is used for collecting a sensing signal of a second stimulation area and performing electro-acupuncture stimulation on the second stimulation area, and the control unit controls the first stimulation unit and the second stimulation unit to perform electro-acupuncture stimulation according to the sensing signals; the control unit comprises a hierarchical coordination module for distributing off-target stimulation parameters, which is divided into a perception layer, a decision layer and an execution layer; the perception layer uploads the sensing signals of the target points to the decision layer in real time; the decision layer distributes the stimulation parameters of the off-target points based on a target point position correlation method; and the execution layer adjusts the output stimulation parameters of the adjacent target points according to the instructions of the decision layer to maintain the total stimulation energy consistent with that before off-target. The present application utilizes the synergistic effect of multiple neural pathways to enhance the contraction function of the pelvic floor muscles and improve the stimulation efficiency.

There are provided a linker compound, for which a glutathione concentration at which a disulfide bond dissociates can be designed by molecular design, and which can accurately identify a cancer cell, is stable outside a target cell, and can effectively release a drug compound in the target cell, and a complex compound containing the same. The linker compound is used for a complex compound containing a drug compound and has a structure represented by the following Formula (1). (In Formula (1), R is a compound containing hydrogen, carbon, oxygen, or a halogen element, or a derivative thereof.

This invention discloses the application of total small molecules of Polygonatum cyrtonema in the preparation of drugs for treating vascular dementia, belonging to the field of natural medicine technology. This invention obtains total small molecules of Polygonatum cyrtonema through a combination of water extraction and alcohol precipitation with macroporous adsorption resin purification. Experiments using a rat model of vascular dementia showed that these total small molecules of Polygonatum cyrtonema effectively improved the degree of neurological function impairment and learning and memory abilities in rats, indicating that the total small molecules of Polygonatum cyrtonema prepared by this invention can effectively treat vascular dementia, providing a new drug source and treatment method for clinical vascular dementia treatment.

This invention belongs to the field of biomedical technology, specifically relating to the application of phyllanthin (PHY) in the preparation of drugs for the treatment or prevention of colitis. The technical problem this invention aims to solve is to provide a new option for the treatment of colitis. The technical solution of this invention is the application of phyllanthin (PHY) in the preparation of drugs for the treatment or prevention of colitis, ulcerative colitis, or Crohn's disease. This invention is applicable to the treatment or prevention of colitis, providing a treatment solution with both "anti-inflammatory" and "barrier repair" functions.

This disclosure pertains to the field of biomedicine, specifically relating to double-stranded oligonucleotides targeting the APP gene and their applications. Specifically, it provides double-stranded oligonucleotide agents or their salts, conjugates, or compositions for inhibiting amyloid precursor protein (APP) expression, wherein the double-stranded oligonucleotide agent comprises a sense strand and an antisense strand forming a double-stranded region; wherein the antisense strand sequence comprises at least 15 consecutive nucleotides of any of the sequences shown in SEQ ID NO:1-154 with a difference of no more than 3 nucleotides, and / or the sense strand sequence comprises at least 15 consecutive nucleotides of any of the sequences shown in SEQ ID NO:155-308 with a difference of no more than 3 nucleotides. The double-stranded oligonucleotide agent or its salt for inhibiting APP expression disclosed in this application can significantly inhibit APP expression and can be used for the prevention and / or treatment of diseases or conditions mediated by the APP gene and / or associated with protein amyloidosis.

This invention provides a traditional Chinese medicine compound preparation for treating vaginitis and its preparation method. The raw materials of the traditional Chinese medicine compound preparation include: 8-12 parts of Callicarpa macrophylla, 8-12 parts of Cnidium monnieri, 3-6 parts of Astragalus membranaceus, 3-6 parts of Sophora flavescens, 3-6 parts of Stemona japonica, 3-6 parts of Kochia scoparia, 3-6 parts of Saposhnikovia divaricata, and 1-2 parts of Gleditsia sinensis. The preparation method is as follows: S1, the raw materials such as Cnidium monnieri are cut into small pieces, the small pieces are expanded under high pressure, and then pulverized to obtain expanded powder; S2, the expanded powder is enzymatically hydrolyzed to obtain enzymatic hydrolysate, then glucose and peptone are added and mixed, and mixed fermentation bacteria are inoculated and cultured by shaking to obtain mixed culture solution; S3, the mixed culture solution is percolated and extracted, the percolate is collected, filtered, and concentrated to obtain compound drug, which is then used to prepare a wash or suppository to obtain the target traditional Chinese medicine compound preparation. The traditional Chinese medicine compound preparation of this invention mainly uses Callicarpa macrophylla and Cnidium monnieri, and works synergistically with Astragalus membranaceus, Sophora flavescens, Stemona japonica and other raw materials to effectively inhibit pathogenic bacteria such as Staphylococcus aureus that cause vaginitis, and can also regulate the vaginal environment to effectively treat vaginitis.

The application provides application of a carbazole derivative Y16 in preparation of a drug for treating cardiovascular diseases, and belongs to the technical field of medicines.The vasodilatation activity of Y16 is determined by using a rat isolated thoracic aorta tension measurement, and the change of the vasodilatation effect of Y16 under the intervention of various channel inhibitors is observed, and the influence of Y16 on blood pressure is determined by using a rat femoral artery cannulation experiment.The results show that the carbazole derivative Y16 has a good dose-dependent vasodilatation effect, and Y16 also shows a blood pressure lowering effect, so that the carbazole derivative Y16 can effectively treat cardiovascular diseases is disclosed for the first time, the application provides a theoretical basis for obtaining a candidate compound of a drug for treating cardiovascular diseases, and also provides a new selection for a drug for treating cardiovascular diseases in clinic.

The application discloses application of ginseng glycoprotein monomer in preparation of a medicine for treating intestinal inflammation, and belongs to the technical field of biological medicine. The ginseng glycoprotein monomer extracted by the application has a molecular weight of 27kDa, a total sugar content of 65.3±2.0%, and a total protein content of 29.9±0.2%. The ginseng glycoprotein monomer can effectively treat Caco-2 cell activity reduction, cell monolayer integrity reduction and inflammatory factor release caused by DSS, and restore tight junction protein ZO-1 and Occludin expression. Therefore, the ginseng glycoprotein monomer can be used for preparing an effective medicine for treating intestinal inflammation.

This invention relates to a novel compound and its uses. The novel compound, its isomers, its pharmaceutically acceptable salts, or its solvates have excellent binding affinity to Cerebrolysin, and therefore can effectively degrade GSPT1 through the E3 ubiquitin ligase activity of the Cerebrolysin complex, thereby enabling effective treatment of diseases including proliferative disorders.

The invention relates to the technical field of biological medicine, and particularly discloses a preparation method of a collagen and anti-propionibacterium acnes gamma protein combined preparation, and the preparation method of the collagen and anti-propionibacterium acnes gamma protein combined preparation comprises the following steps: preparing anti-propionibacterium acnes gamma protein; adding water into the anti-propionibacterium acnes gamma protein and the recombinant III-type collagen, stirring and mixing, adding glycerol and a neutralizing agent, and mixing to obtain a uniform solution; the preparation method comprises the following steps: dispersing carbomer with water, adding a preservative and a humectant, mixing, finally adding the uniform solution, and mixing to obtain the required collagen and anti-propionibacterium acnes gamma protein combined preparation. The combined preparation prepared by the method can be used for effectively treating acnes, is remarkable in curative effect, does not generate drug resistance, is short in treatment cycle, can quickly eliminate skin damage, promote cell growth and adhesion and repair skin barriers, and does not generate new rash after healing.

The present application finds that ITIH4 secreted by macrophages can promote the viability and repair of intestinal epithelial cells, promote the expression of intestinal tight junction protein ZO-1, and inhibit the expression of macrophage inflammatory factors, and is an effective molecule for treating intestinal inflammation. Based on this, the present application provides the use of ITIH4 in the preparation of a medicament for treating intestinal inflammation.

This invention provides a traditional Chinese medicine composition for treating allergic rhinitis, its preparation method, and its application. The effective components of the traditional Chinese medicine composition are made from the following raw materials in parts by weight: Astragalus membranaceus 3-50, Atractylodes macrocephala 3-30, Saposhnikovia divaricata 3-30, Magnolia biondii 3-30, Xanthium sibiricum (fried) 3-30, Ganoderma lucidum 3-50, Platycodon grandiflorus 3-30, calcined dragon bone 5-50, calcined oyster shell 5-50, Terminalia chebula 3-30, Adenophora stricta 3-30, Cordyceps sinensis mycelium powder 3-30, and Dictamnus dasycarpus 3-30. The raw materials of this traditional Chinese medicine composition are common, the preparation method is simple and easy to operate, and it has wide application value. Oral administration of the drug significantly improves nasal sensitivity symptoms in a mouse model of allergic rhinitis, reduces the levels of IgE and histamine in serum and nasal lavage fluid, reduces the level of inflammatory factors in serum, and inhibits the number of inflammatory cells and mast cells in the nasal mucosa, thus effectively treating allergic rhinitis.

This invention discloses an orally disintegrating film formulation of BPC-157 sodium salt for treating acute alcohol poisoning and its preparation method. It relates to the field of acute alcohol poisoning treatment technology. The orally disintegrating film formulation comprises, by weight percentage: 0.1-5% BPC-157 sodium salt, 40-70% film-forming material, 5-15% plasticizer, 0.1-15% disintegrant, 0.1-15% sweetener, 0.1-10% salivary stimulant, and 1-5% other excipients. This invention prepares an orally disintegrating film formulation of BPC-157 sodium salt, utilizing its rapid dissolution characteristics and the pharmacological effects of BPC-157, providing a new option for treating acute alcohol poisoning. This formulation has advantages such as rapid onset of action, high bioavailability, and few side effects, and is expected to become an effective drug for treating acute alcohol poisoning.

This invention provides the application of extracellular vesicle-like particles derived from *Calamus esculenta* in the preparation of drugs for treating cancer. This invention establishes a feasible method for isolating extracellular vesicles from the plant *Calamus esculenta*. This extraction process is simple, stable, and reliable, and can obtain high-purity *Calamus esculenta* extracellular vesicle products, effectively solving the technical difficulties in isolating plant-derived extracellular vesicles. This invention is the first to discover that *Calamus esculenta*-derived extracellular vesicle-like particles can inhibit the proliferation and / or migration of cervical cancer cells or glioma cells, and that these particles can effectively treat cervical cancer or glioma. This invention provides a novel strategy for cancer treatment and has broad therapeutic prospects.

This invention discloses an adaptive drug delivery system for ischemic stroke, its preparation method, and its application. MMP-2 responsive peptide-drug dimers are loaded onto the surface of mesoporous polydopamine for intervention or treatment of cerebral ischemia-reperfusion injury. The system allows for targeted drug delivery based on individual differences in disease progression among patients, precisely promoting brain injury repair. This invention applies MMP-2 responsive peptides to the treatment of ischemic stroke, using mesoporous polydopamine as a drug carrier, providing reactive sites and loading space for efficient drug loading. The chemical reaction between catechol on the polydopamine surface and the thiol groups on the MMP-2 responsive peptides loads the peptide-drug dimers, thereby achieving responsive drug release on the carrier surface. Simultaneously, this invention utilizes the ability of polydopamine to scavenge reactive oxygen species (ROS), rapidly clearing local ROS and reducing acute damage caused by ischemic stroke.

This invention relates to a traditional Chinese medicine composition for delaying the progression of kidney deficiency and blood stasis syndrome in diabetic nephropathy, its application, and preparation method. The composition is made from Astragalus membranaceus, Salvia miltiorrhiza, Paeonia lactiflora, Anemarrhena asphodeloides, Phellodendron chinense, Cistanche deserticola, Scutellaria baicalensis, Euonymus alatus, Schisandra chinensis, raw oyster shell, Plantago asiatica, and Artemisia annua. It has the effects of nourishing the kidneys, clearing heat, eliminating toxins, and unblocking the meridians. This traditional Chinese medicine composition can effectively delay the decline in renal function in patients with massive proteinuria during the diabetic nephropathy stage, improve the clinical symptoms of patients with kidney deficiency and blood stasis syndrome, and improve their quality of life. Simultaneously, it has a low risk of hyperkalemia and gastrointestinal bleeding, and no significant damage to liver function has been observed, indicating high safety.

This invention relates to the field of aspirin medicinal chemistry, and particularly to an aspirin-dithiocarbamate hybrid, its preparation method, and its applications. The preparation method uses aspirin (ASP) as the parent compound and involves a three-step reaction: acylation, dithiocarbamate formation, and N-acylation. During this reaction, several novel aspirin-dithiocarbamate hybrids (3a–l) can be efficiently synthesized through a single silica gel column chromatography separation and purification step, making the preparation process simple. The prepared aspirin-dithiocarbamate hybrids significantly enhance the toxicity of human lung cancer cells A549, approximately eight times that of the parent compound ASP, and are comparable to the anticancer drug irinotecan. The prepared aspirin-dithiocarbamate hybrid 3f exhibits inhibitory effects on various cancer cells and can inhibit the growth of human lung cancer A549 cells by inducing cell cycle arrest in the G0 / G1 phase.

The present invention provides a dental examination system and method, more specifically, generating a plurality of healthy tooth data; receiving scan data from the three-dimensional scanner; extracting standard healthy tooth data from the plurality of healthy tooth data; comparing the scan data with the standard healthy tooth data to generate detection data; and transmitting the detection data to the user terminal through the communication network.

This invention relates to a novel multispecific binding protein for cancer treatment, namely the B7H6 / CD3 binding protein. The invention also relates to nucleic acids encoding said protein; methods for preparing said protein; host cells expressing or capable of expressing said protein; compositions comprising said protein; and uses of said protein or said composition, particularly for therapeutic purposes in the field of cancer.

Provided are recombinant adeno-associated virus (rAAV) vectors comprising one or two of (a) to (c): (a) a nucleotide sequence encoding an aromatic L-amino acid decarboxylase (AADC); (b) a nucleotide sequence encoding a glucocerebrosidase (GBA1); and (c) a nucleotide sequence encoding a neurotrophic factor (NTF) such as a brain dopamine neurotrophic factor (CDNF) or a glial cell-derived neurotrophic factor (GDNF), for use in the treatment of neurodegenerative disorders, in particular Parkinson's disease (PD), multiple system atrophy (MSA), Gaucher's disease (GD), and other proteinopathies. Also provided herein are viral particles comprising the rAAV vectors, pharmaceutical compositions comprising the viral particles, and uses thereof.

Application of a multifunctional supramolecular nanoplatform drug: The application of a multifunctional supramolecular nanoplatform in the preparation of drugs for liver ischemia-reperfusion injury. The multifunctional supramolecular nanoplatform is a GalAC4A supramolecular carrier loaded with naringenin (NAR). The multifunctional supramolecular nanoplatform is prepared from naringenin (NAR), galactose (Gal), and CAC4A from azocalixarene. The multifunctional supramolecular nanoplatform is a NAR@GalAC4A nanocomposite. The multifunctional supramolecular nanoplatform achieves hepatocyte-specific targeting through desialyl glycoprotein receptor-mediated endocytosis. This invention proposes a novel "receptor recognition-hypoxia response-synergistic therapy" three-pronged design strategy, successfully constructing a GalAC4A supramolecular carrier loaded with naringenin (NAR) to form a NAR@GalAC4A nanocomposite.

The present application relates to a kind of synbiotic preparation, comprising: probiotic or its bacterial lysate, fermentation product, wherein probiotic is one or more selected from the following group: Bifidobacterium, Streptococcus, Lactobacillus, Saccharomycete, Escherichia coli;Prebiotic is one or more selected from the following group: breast milk oligosaccharide, fructo-oligosaccharide, inulin, lactulose, galacto-oligosaccharide, soybean oligosaccharide, resistant dextrin, xylo-oligosaccharide, isomalto-oligosaccharide, chitooligosaccharide;And wall material;The probiotic or its bacterial lysate, fermentation product is coupled with prebiotic, and wall material is wrapped in the coupling product.The synbiotic preparation of the application is simple, no chemical drug or antibiotic component is added, can repair damaged intestinal mucosal barrier, reduce intestinal permeability, regulate immune balance, optimize flora structure, so as to more effectively treat colitis.In addition, it is convenient to use, easy to promote in farm.

This invention relates to the field of medical pharmaceutical technology, and in particular to the application of peony oil in the preparation of a drug for treating benign prostatic hyperplasia (BPH). The preparation method of the peony oil includes the following steps: selecting peony plants, peeling peony seeds from the plants as raw materials, crushing and grinding the dried peony seeds using a crushing device to obtain granular raw materials, placing the granular raw materials in a container and adding an organic solution, soaking them in a cool place, then heating and refluxing for extraction, collecting the volatile oil to obtain peony oil, and filtering the peony oil through multiple layers to form peony oil. The application of this peony oil in the preparation of a drug for treating BPH utilizes abundant raw materials for peony oil extraction, and the preparation method is simple and low-cost. Peony flowers are used as the sole active ingredient in the extraction of peony oil, which can be effectively used to treat BPH, expanding the medicinal value of peony flowers and alleviating the suffering of patients during their illness.

This invention is a divisional application of application number 202010500967.1. The invention relates to a layered double hydroxide material system, its preparation method, and its application, specifically the application of LDH / EDTA layered double hydroxide materials in the preparation of antitumor drugs. The LDH / EDTA layered double hydroxide material is a zinc-aluminum layered double hydroxide loaded with ethylenediaminetetraacetic acid (EDTA); in the EDTA-loaded zinc-aluminum layered double hydroxide, EDTA is anion-exchange-intercalated into the interlayer space of the zinc-aluminum layered double hydroxide; the surface of the EDTA-loaded zinc-aluminum layered double hydroxide is positively charged.

This invention discloses an injectable hydrogel for photothermal-assisted treatment of periodontitis and its preparation method, belonging to the field of polymer material preparation technology. The preparation method includes the following steps: reacting MXene dispersion with epigallocatechin gallate and MgSO4; then sequentially performing ultrasonication, centrifugation, washing, and lyophilization to obtain multifunctional nanosheets MP-Mg; adding the multifunctional nanosheets MP-Mg to an aqueous solution of oxidized gellan gum for mixing to obtain solution A; mixing equal volumes of quaternary ammonium chitosan aqueous solution and carboxymethyl chitosan aqueous solution for reaction to obtain solution B; and mixing equal volumes of solution A and solution B for further reaction. The hydrogel prepared by this invention possesses injectability, photothermal responsiveness, biofilm penetration ability, synergistic antibacterial properties, and long-lasting anti-inflammatory effects, providing an innovative and practical photothermal-assisted treatment platform for the clinical treatment of periodontitis.